---

(Bloomberg) - Impax Laboratories Inc. (IPXL), the developer of the experimental drug Rytary for Parkinson’s disease, fell the most in almost three years after regulators found that manufacturing issues persist at a company plant.

Impax declined 25% to $15.03 at 11:03 a.m. New York time, after falling to $14.88 in the biggest intraday drop since May 2010.

Read more.